Argenx’s 1st Med in Japan Vyvgart Now Available for Generalized Myasthenia Gravis

May 10, 2022
Argenx Japan rolled out its generalized myasthenia gravis (gMG) drug Vyvgart (efgartigimod alfa) in Japan on May 9, making it the company’s first product launched in the country. A neonatal Fc receptor (FcRn) blocker, Vyvgart is expected to generate peak...read more